Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

Running, not enrolling · Phase 1

Conditions studied: Relapsed/Refractory Large B-cell Lymphoma

In brief

This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in participants with relapsed or refractory large B-cell lymphoma (r/rLBCL). The goal of Phase 1b of this clinical study is learn about the effectiveness of the recommended dose of KITE-197 in participants with r/r LBCL. The primary objectives of this study are: Phase 1a: To evaluate the safety of KITE-197 in participants with r/r LBCL and determine the target dose level for Phase 1b. Phase 1b: To evaluate the efficacy of KITE-197 in participants with r/r LBCL as measured by the complete remission (CR) rate.

Key facts

Study ID: NCT06079164
Run by: Kite, A Gilead Company
People needed: 39
Starts: 2023-11-09
Expected to finish: 2026-07-01
Last updated by the study team: 2026-01-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Sylvester Comprehensive Cancer Center — Miami, Florida, United States
University of Chicago Medical Center — Chicago, Illinois, United States
Henry-Joyce Cancer Clinic — Nashville, Tennessee, United States
St. David's South Austin Medical Center — Austin, Texas, United States
Swedish Cancer Institute — Seattle, Washington, United States
Royal Prince Alfred Hospital — Camperdown, New South Wales, Australia
Royal Brisbane and Women's Hospital — South Brisbane, Queensland, Australia
The Alfred Hospital — Melbourne, Victoria, Australia
Cross Cancer Institute — Edmonton, Canada
QEII Health Sciences Centre — Halifax, Canada
Jewish General Hospital — Montreal, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.